Otsuka (OTCMKTS:OTSKY – Get Free Report) and RYTHM (NASDAQ:RYM – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.
Volatility & Risk
Otsuka has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, RYTHM has a beta of 9.94, suggesting that its share price is 894% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Otsuka and RYTHM, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Otsuka | 1 | 2 | 1 | 0 | 2.00 |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
Earnings & Valuation
This table compares Otsuka and RYTHM”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Otsuka | $16.51 billion | 2.51 | $2.43 billion | $2.33 | 16.58 |
| RYTHM | $70.82 million | 0.29 | -$33.26 million | ($5.27) | -1.82 |
Otsuka has higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Otsuka, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Otsuka and RYTHM’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Otsuka | 14.36% | 11.90% | 8.91% |
| RYTHM | 9.84% | 21.25% | 5.51% |
Insider & Institutional Ownership
6.0% of RYTHM shares are held by institutional investors. 3.5% of RYTHM shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Otsuka beats RYTHM on 9 of the 13 factors compared between the two stocks.
About Otsuka
Otsuka Holdings Co., Ltd. is a Japan-based holding company whose businesses focus primarily on pharmaceuticals and nutraceuticals. Its group companies research, develop, manufacture, and market prescription medicines, consumer health products, and medical devices. Otsuka’s pharmaceutical portfolio includes treatments across areas such as mental health, kidney disease, and oncology. Its nutraceutical business offers products including Pocari Sweat and CalorieMate, alongside other nutrition and wellness products.
About RYTHM
I couldn’t verify a Nasdaq-listed company named RYTHM with the ticker RYM. If you mean Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), it is a biopharmaceutical company developing treatments for rare genetic diseases and other conditions linked to the brain’s melanocortin-4 receptor pathway, which helps regulate hunger and body weight. Its marketed medicine, Imcivree (setmelanotide), is approved in the United States for certain forms of rare genetic obesity and acquired hypothalamic obesity. The company is based in Boston and focuses on developing and providing therapies for patients in the United States and other markets.
Receive News & Ratings for Otsuka Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otsuka and related companies with MarketBeat.com's FREE daily email newsletter.
